<DOC>
	<DOC>NCT01726023</DOC>
	<brief_summary>The purpose of this study is to evaluate the effects of Ceftazidime Avibactam plus Metronidazole compared to Meropenem for treating hospitalized patients with complicated intra-abdominal infections.</brief_summary>
	<brief_title>Compare Ceftazidime-Avibactam + Metronidazole vs Meropenem for Hospitalized Adults With Complicated Intra-Abd Infections</brief_title>
	<detailed_description>A Phase III, Randomized, Multicenter, Double Blind, Double-Dummy, Parallel-Group, Comparative Study to Determine the Efficacy, Safety, and Tolerability of Ceftazidime Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-Abdominal Infections In Hospitalized Adults</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Intraabdominal Infections</mesh_term>
	<mesh_term>Meropenem</mesh_term>
	<mesh_term>Thienamycins</mesh_term>
	<mesh_term>Ceftazidime</mesh_term>
	<mesh_term>Avibactam</mesh_term>
	<mesh_term>Avibactam, ceftazidime drug combination</mesh_term>
	<mesh_term>Metronidazole</mesh_term>
	<criteria>Patient must be 18 to 90 years of age, inclusive, Female patients can participate if they are surgically sterilized or postmenopausal for at least 1 year or her sexual partner has had a vasectomy Female of childbearing potential has had normal menstrual periods for 3 months and negative serum pregnancy test and agree to practice highly effective methods of birth control during treatment and for at least 7 days after last dose Intraoperative/postoperative enrollment with visual confirmation (presence of pus within the abdominal cavity) of an intraabdominal infection associated with peritonitis Confirmation of infection by surgical intervention within 24 hours of entry: evidence of systemic inflammatory indicators; physical findings consistent with intraabdominal infection; supportive radiologic imaging findings of intraabdominal infections Patient is diagnosed with traumatic bowel perforation undergoing surgery within 12 hours; perforation of gastroduodenal ulcers undergoing surgery within 24 hours. Other intraabdominal processes in which primary etiology is not likely to be infectious Patient has abdominal wall abscess or bowel obstruction without perforation or ischemic bowel without perforation Patients whose surgery will include staged abdominal repair, or "open abdomen" technique, or marsupialization Patient has suspected intraabdominal infections due to fungus, parasites, virus or tuberculosis Patient is considered unlikely to survive the 6 to 8week study period or has a rapidly progressive or terminal illness, including septic shock that is associated with a high risk of mortality</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Ceftazidime-avibactam,</keyword>
	<keyword>Metronidazole,</keyword>
	<keyword>Meropenem,</keyword>
	<keyword>Anti-Bacterial Agents,</keyword>
	<keyword>Anti-Infective Agents,</keyword>
	<keyword>Therapeutic Uses,</keyword>
	<keyword>Pharmacologic Actions,</keyword>
	<keyword>Physiological Effects of Drugs</keyword>
</DOC>